Showing 2931-2940 of 4166 results for "".
- Staar Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreementhttps://modernod.com/news/staar-surgical-and-kobe-kanagawa-eye-clinic-in-japan-announce-strategic-cooperation-agreement/2480068/Staar Surgical and Kobe Kanagawa Eye Clinic, with locations in Tokyo and Osaka, announced they have entered into a multi-year Strategic Cooperation Agreement to provide Staar’s EVO Visian ICL lenses as a primary and premium option for patients seeking visual freedom from spectacles and cont
- GenSight Biologics Reports Positive Additional Data From REVERSE Phase 3 Clinical Trial of GS010 for Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-positive-additional-data-from-reverse-phase-3-clinical-trial-of-gs010-for-treatment-of-leber-hereditary-optic-neuropathy-lhon/2480100/GenSight Biologics reported additional results from the REVERSE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4)in patients with Leber Hereditary Optic Neuropathy (LHON). The study involved 37 patients with visual loss du
- Bausch + Lomb Enrolls First Patient in Envista MX60EF Trifocal IOL Clinical Trialhttps://modernod.com/news/bausch-lomb-enrolls-first-patient-in-envista-mx60ef-trifocal-iol-clinical-trial/2480122/Bausch + Lomb announced that it has enrolled the first patient in a clinical trial studying the efficacy and safety of an investigational trifocal IOL, the enVista MX60EF. The study is intended to support a premarket approval (PMA) application filing with the FDA. The enVista MX60EF trifoc
- Clearside Biomedical Announces Topline Results from Phase 2 Clinical Trial of DME Combination Drughttps://modernod.com/news/clearside-biomedical-announces-positive-topline-results-from-phase-2-clinical-trial-of-dme-combination-drug/2480130/Clearside Biomedical announced positive topline results from its phase 2 clinical trial evaluating suprachoroidal CLS-TA used with intravitreally administered Eylea (aflibercept) in patients with diabetic macular edema (DME) over a 6-month evaluation period, according to a company news release.</
- Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC for the Treatment of Glaucomahttps://modernod.com/news/ocular-therapeutix-announces-treatment-of-first-patient-in-phase-1-clinical-trial-of-otx-tic-for-the-treatment-of-glaucoma-and-ocular-hypertension/2480177/Ocular Therapeutix announced the treatment of the first patient in a phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of IOP in patients with glaucoma
- FDA Approves Eyenovia’s IND Application for MicroLine for Presbyopia, Allowing for Phase 3 Trialshttps://modernod.com/news/fda-approves-eyenovias-ind-application-for-microline-for-presbyopia-allowing-for-phase-3-trials/2478620/Eyenovia announced that the FDA has accepted its investigational new drug (IND) application for MicroLine, a proprietary pilocarpine formulation for the improvement in near vision in patients with presbyopia. The company intends to initiate the phase 3 VISION program, beginning with the VISION-1
- Versant Health Debuts New Eye Care Resource Centerhttps://modernod.com/news/versant-health-debuts-new-eye-care-resource-center/2477925/In celebration of Healthy Vision Month this July, Versant Health has launched a new resource center providing tools that enable people to take command of their vision health. Designated by the National Eye Institute, Healthy Vision Month is dedicated to highlighting the importance of eye h
- OneSight EssilorLuxottica Foundation Encourages Eye Doctors to Adopt a Local School and Help More Kids See Clearlyhttps://modernod.com/news/onesight-essilorluxottica-foundation-encourages-eye-doctors-to-adopt-a-local-school-and-help-more-kids-see-clearly/2481702/Good vision is a basic human right, but one in four schoolchildren
- EssilorLuxottica and CooperCompanies Finalize Joint Venturehttps://modernod.com/news/essilorluxottica-and-coopercompanies-finalize-joint-venture/2480705/EssilorLuxottica and CooperCompanies have announced the finalization of their joint venture agreement for SightGlass Vision. This collaboration accelerates the commercialization of novel spectacle lens technologies to expand the myopia management category. SightGlass Vision’s Diffusion
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul